Benitec said this week that it has received a $161,674 dividend related to its stake in privately held RNAi drug shop Tacere Therapeutics.
In 2006, Benitec licensed its gene-silencing technology to Tacere for use in developing an expressed RNA-based treatment for hepatitis C (GSN 10/12/2006). The equity stake was part of the payment Benitec received for the license.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
